ES2180555T3 - Nueva substancia fisiologicamente activa. - Google Patents

Nueva substancia fisiologicamente activa.

Info

Publication number
ES2180555T3
ES2180555T3 ES94115306T ES94115306T ES2180555T3 ES 2180555 T3 ES2180555 T3 ES 2180555T3 ES 94115306 T ES94115306 T ES 94115306T ES 94115306 T ES94115306 T ES 94115306T ES 2180555 T3 ES2180555 T3 ES 2180555T3
Authority
ES
Spain
Prior art keywords
active substance
physiologically active
action
agent
blood flow
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94115306T
Other languages
English (en)
Inventor
Jin-Emon Konishi
Giichi Hamada
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nippon Zoki Pharmaceutical Co Ltd
Original Assignee
Nippon Zoki Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Zoki Pharmaceutical Co Ltd filed Critical Nippon Zoki Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2180555T3 publication Critical patent/ES2180555T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13Tumour cells, irrespective of tissue of origin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/36Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/76Viruses; Subviral particles; Bacteriophages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

SE OFRECE UNA NUEVA SUSTANCIA FISIOLOGICAMENTE ACTIVA QUE EXHIBE UNA ACCION INHIBIDORA DE PRODUCCION DE ENZIMAS PROTEOLITICAS EN PLASMA, ACCION MEJORADORA DE FLUJO PERIFERICO EN SANGRE Y ACCIONES ANALGESICAS, ANTIINFLAMATORIAS Y ANTIALERGICAS. LA SUSTANCIA FISIOLOGICAMENTE ACTIVA DE LA PRESENTE INVENCION ES PREPARADA ACTIVANDO DIVERSOS ANIMALES O TEJIDOS ANIMALES POR MEDIO DE INOCULACION DE VIRUS O CELULAS TUMORALES QUE ACTUAN COMO UN AGRESIVO PSIQUICO Y ENTONCES EXTRAYENDO EL FACTOR EFECTIVO DE LOS TEJIDOS ACTIVADOS. LA INVENCION ES RELATIVA A UNA SUSTANCIA QUE EXHIBE UNA ACCION FARMACOLOGICA DE INHIBICION DE UNA ACTIVIDAD PARA LA PRODUCCION DE ENZIMAS PROTEOLITICAS EN PLASMA Y RECUPERA Y NORMALIZA LA FUNCION ANORMAL QUE RESULTA EN EL ESTADO DE ENFERMEDAD. LA SUSTANCIA FISIOLOGICAMENTE ACTIVA DE LA PRESENTE INVENCION EXHIBE UNA EXCELENTE ACTIVIDAD REGULADORA PARA BIOFUNCIONES, TIENE UNA ACCION DE RECUPERACION Y NORMALIZACION DE FUNCION ANORMAL DE LOS ORGANISMOS VIVOS EN DIVERSOS ESTADOS DEENFERMEDAD Y ES BASTANTE USADA COMO UN FARMACO TAL COMO UN AGENTE MEJORADOR DE FLUJO SANGUINEO, AGENTE ANALGESICO, AGENTE ANTIINFLAMATORIO Y AGENTE ANTIALERGICO.
ES94115306T 1993-09-28 1994-09-28 Nueva substancia fisiologicamente activa. Expired - Lifetime ES2180555T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP5265589A JP2594222B2 (ja) 1993-09-28 1993-09-28 新規生理活性物質−kf

Publications (1)

Publication Number Publication Date
ES2180555T3 true ES2180555T3 (es) 2003-02-16

Family

ID=17419225

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94115306T Expired - Lifetime ES2180555T3 (es) 1993-09-28 1994-09-28 Nueva substancia fisiologicamente activa.

Country Status (14)

Country Link
US (1) US5560935A (es)
EP (1) EP0645142B1 (es)
JP (1) JP2594222B2 (es)
KR (1) KR100189144B1 (es)
CN (1) CN1062182C (es)
AT (1) ATE220913T1 (es)
AU (1) AU676081B2 (es)
CA (1) CA2132993C (es)
DE (1) DE69431024T2 (es)
DK (1) DK0645142T3 (es)
ES (1) ES2180555T3 (es)
PT (1) PT645142E (es)
SG (1) SG45225A1 (es)
TW (1) TW326028B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2588109B2 (ja) * 1993-03-19 1997-03-05 日本臓器製薬株式会社 鎮痛剤
JPH1084995A (ja) * 1996-09-12 1998-04-07 Nippon Zoki Pharmaceut Co Ltd 血液凝固第xii因子活性化法
JP4033936B2 (ja) * 1997-01-08 2008-01-16 日本臓器製薬株式会社 一酸化窒素産生抑制剤
JPH1180005A (ja) * 1997-09-12 1999-03-23 Nippon Zoki Pharmaceut Co Ltd 骨粗鬆症治療剤
JPH11139977A (ja) * 1997-11-07 1999-05-25 Nippon Zoki Pharmaceut Co Ltd Nef作用抑制剤
KR19990044835A (ko) * 1997-11-28 1999-06-25 고니시 진우에몬 생약추출물
AU763224B2 (en) * 1999-04-15 2003-07-17 Nippon Zoki Pharmaceutical Co., Ltd. Novel bioactivating substance
EP1110909A1 (en) * 1999-12-24 2001-06-27 Bio Minerals N.V. Method for preparing ortho silicic acid, ortho silicic acid as obtained, and its use
US6726932B2 (en) 2000-02-18 2004-04-27 Nippon Zoki Pharmaceutical Co., Ltd. Fatty acid-containing composition
EP1420641A4 (en) * 2001-08-01 2005-05-25 Anil K Chauhan IMMUNE COMPLEX
US6913900B2 (en) * 2001-08-29 2005-07-05 Nippon Zoki Pharmaceutical Co., Ltd. Plasma prekallikrein activation and kallikrein production assay
AU2003280684B2 (en) 2002-10-31 2009-06-25 Nippon Zoki Pharmaceutical Co., Ltd. Remedy for fibromyalgia
CN1207005C (zh) 2002-10-31 2005-06-22 威世药业(如皋)有限公司 含生物活性物质的兔皮和其用途
KR101307999B1 (ko) * 2004-12-01 2013-09-12 니폰 조키 세야쿠 가부시키가이샤 건조물 및 그 제조방법
US20060134646A1 (en) 2004-12-17 2006-06-22 Ansari Aftab A Method for treatment of HIV infection
US7252834B2 (en) * 2005-04-25 2007-08-07 Clemson University Research Foundation (Curf) Elastin stabilization of connective tissue
TWI406664B (zh) 2006-03-30 2013-09-01 Univ Kyoto 硫氧還蛋白(thioredoxin)產生促進劑
JP4300370B2 (ja) 2007-03-13 2009-07-22 春三 小林 上皮改善剤
EP2191836B1 (en) 2007-08-31 2012-05-23 Kyushu University, National University Corporation Prophylactic or alleviating agent for peripheral nerve disorder induced by anti-cancer agent
TWI483729B (zh) 2010-03-11 2015-05-11 Nippon Zoki Pharmaceutical Co 慢性前列腺炎、間質性膀胱炎及/或排尿障礙之改善或治療劑
WO2011162317A1 (ja) 2010-06-25 2011-12-29 日本臓器製薬株式会社 被検物質の判定又は評価方法
EP2627343B1 (en) 2010-10-14 2018-01-10 Nippon Zoki Pharmaceutical Co., Ltd. Agents for use for promoting the synthesis of collagen and proteoglycan in intervertebral disc cells
CN103357006B (zh) 2012-10-10 2014-10-15 日本脏器制药株式会社 含有提取物的制剂的检查方法
CA2909234C (en) 2013-04-30 2023-03-14 Nippon Zoki Pharmaceutical Co., Ltd. Extracts and preparation thereof from inflamed skins of rabbits inoculated with vaccinia virus
CN108738345A (zh) 2016-02-24 2018-11-02 国立大学法人大阪大学 试验方法
WO2018056412A1 (ja) 2016-09-23 2018-03-29 国立大学法人大阪大学 シュワン細胞分化促進剤及び末梢神経再生促進剤

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB697351A (en) * 1951-01-16 1953-09-23 Masuichi Takino Improved process for the manufacture of nerve sedatives
US3959566A (en) * 1974-10-21 1976-05-25 E. I. Du Pont De Nemours And Company Process for preparing polymeric surfaces to improve antistatic and soil resistant properties
US4036787A (en) * 1975-09-12 1977-07-19 Blount David H Process for the production of epoxy silicate compounds and polymers
US4039474A (en) * 1975-10-20 1977-08-02 Nalco Chemical Company Silica-alumina catalysts
US4056937A (en) * 1976-01-08 1977-11-08 Kyokado Engineering Co. Ltd. Method of consolidating soils
US4089883A (en) * 1976-07-09 1978-05-16 Blount David H Process for the production of organic hydroxy silicate compounds and their condensation products
US4104456A (en) * 1977-01-06 1978-08-01 Blount David H Process for the production of poly(allylhalide-allyl alcohol)
JPS53101515A (en) * 1977-02-17 1978-09-05 Nippon Zoki Pharmaceutical Co Medicine having anodyne * sedative and antiallergic activity and production thereof
JPS5777697A (en) * 1980-11-04 1982-05-15 Nippon Zoki Pharmaceut Co Ltd Physiologically active substance nsq
JPS57183720A (en) * 1981-05-01 1982-11-12 Junji Mitani Health drug for fish farming
JPS5835117A (ja) * 1981-08-25 1983-03-01 Nippon Zoki Pharmaceut Co Ltd 新規生理活性物質nsh
JPS59118711A (ja) * 1982-12-25 1984-07-09 Nippon Zoki Pharmaceut Co Ltd 新規生理活性物質
JPS63185398A (ja) * 1986-09-10 1988-07-30 Nippon Zoki Pharmaceut Co Ltd 生理活性物質測定法
JP2651674B2 (ja) * 1987-07-23 1997-09-10 日本臓器製薬 株式会社 新規生理活性物質及びその製造方法
US4863518A (en) * 1987-10-19 1989-09-05 Blount David H Production of polyol-alkali metal silicate glass emulsion
JP2539674B2 (ja) * 1987-11-06 1996-10-02 日本臓器製薬株式会社 新規生理活性物質
US4985254A (en) * 1987-11-06 1991-01-15 Nippon Zoki Pharmaceutical Co., Ltd. Method of treating ischemic diseases
EP0341209B1 (en) * 1988-04-30 1993-09-15 Nippon Zoki Pharmaceutical Co. Ltd. Physiologically active substances, a process for preparation and pharmaceutical compositions thereof
SE461156B (sv) * 1988-05-25 1990-01-15 Eka Nobel Ab Saett foer framstaellning av papper varvid formning och avvattning aeger rum i naervaro av en aluminiumfoerening, ett katjoniskt retentionsmedel och en polymer kiselsyra
JP2539665B2 (ja) * 1988-06-20 1996-10-02 日本臓器製薬株式会社 神経疾患治療剤
CA2052449C (en) * 1990-10-01 2000-08-01 Takao Hasegawa Flocculant for water treatment and method for producing it

Also Published As

Publication number Publication date
DE69431024T2 (de) 2003-01-30
SG45225A1 (en) 1998-01-16
EP0645142B1 (en) 2002-07-24
CA2132993C (en) 1999-10-26
AU7437494A (en) 1995-04-13
DK0645142T3 (da) 2002-11-04
KR960010010A (ko) 1996-04-20
DE69431024D1 (de) 2002-08-29
US5560935A (en) 1996-10-01
CN1107365A (zh) 1995-08-30
KR100189144B1 (ko) 1999-06-01
JPH0797336A (ja) 1995-04-11
PT645142E (pt) 2002-12-31
JP2594222B2 (ja) 1997-03-26
AU676081B2 (en) 1997-02-27
CA2132993A1 (en) 1995-03-29
TW326028B (en) 1998-02-01
CN1062182C (zh) 2001-02-21
ATE220913T1 (de) 2002-08-15
EP0645142A1 (en) 1995-03-29

Similar Documents

Publication Publication Date Title
ES2180555T3 (es) Nueva substancia fisiologicamente activa.
CY1119951T1 (el) Συνθεσεις για αυξηση δραστηριοτητας τελομερασης και αγωγη λοιμωξης hiv
HUP9800028A2 (hu) Több tumor esetében rendellenes sejtszaporodás előidézésében közrejátszó gének
DE69907508D1 (de) Mikrobenbeständige und stabilisierte lösungen, die gamma-hydroxybuttersäuresalze zur behandlung von narkolepsie enthalten
DE69815122T2 (de) Saccharid-enthaltende zubereitungen zur behandlung von alzheimerschen erkrankung und von weiteren amyloidosen
DE68915834D1 (de) Herstellung von T-Zellen und T-Zellmembranen, verwendbar zur Verhütung und Behandlung von Autoimmunkrankheiten.
ATE83659T1 (de) Verwendung von indolon-derivaten zur herstellung von arzneimitteln zur behandlung des parkinsonismus.
DE69528039D1 (de) Inhibitoren der fettsäuresynthese als antimikrobielle mittel
ATE314063T1 (de) Valproinsäure zur behandlung von brustkrebs, dickdarmkrebs, kopf-hals-krebs, kleinzelligem lungenkarzinom und blutzellenkrebs in kombination mit bestrahlung
BR0313371A (pt) Composto, uso de um composto e método de tratamento de doença
Koundinya et al. Effect of organophosphate pesticide Sumithion (Fenitrothion) on some aspects of carbohydrate metabolism in a freshwater fish, Sarotherodon (Tilapia) mossambicus (Peters)
DE502004008819D1 (de) Medikament zur wachstumsinhibierung von tumoren
ATE412769T1 (de) Nadh-oxidase als zielmolekül in diagnose und therapie
KR950700079A (ko) 이식체-대-숙주 질환을 억제하기 위한 인터루킨-10의 용도(Use of interleukin-10 to suppress graft-vs. -host disease)
SE0102147D0 (sv) New methods
HUP9901188A2 (hu) Új, meghatározott enzimkeverékek sejtkinyeréshez és sebkezeléshez
ATE322244T1 (de) Verwendung von polyaminosäurederivaten zur behandlung von seborrhoe und verwandten hautstörungen
AU664974B2 (en) Accelerated wound healing
NO995838L (no) Nye heteroetynylenforbindelser og farmasoeytiske og kosmetiske preparater inneholdende de samme
DE19681032D2 (de) Gentherapeutisches Nukleinsäurekonstrukt, seine Herstellung und Verwendung zur Behandlung von Herzerkrankungen
DE602004030661D1 (de) Verwendung von kahalalide verbindungen zur herstellung eines arzneimittels zur behandlung von psoriasis
DE50103012D1 (de) Verwendung von hyaluronidase zur prophylaxe und behandlung von herz-kreislauf-erkrankungen
PT883406E (pt) Utilizacao da il-7 no tratamento das doencas auto-imunes em particular a diabetes mellitus insulinodependente
DE69428797T2 (de) Verwendung von benzydamin zur behandlung von krankheitszuständen, die durch tnf verursacht werden
DE69421705D1 (de) Verwendung von Efaroxan und dessen Derivaten zur Herstellung eines Arzneimittels zur Behandlung neurogenerativer Erkrankungen